Order results by:
| Issue | Title | |
| Vol 14, No 4 (2021) | Peptides of Laennec® preparation that contribute to the elimination of endotheliopathy | Abstract similar documents |
| I. Yu. Torshin, О. А. Gromova, V. G. Zgoda, А. G. Chuchalin, V. А. Maksimov, О. V. Tikhonova | ||
| "... Objective: identification of peptides in the composition of Laennec®, which can inhibit ..." | ||
| Vol 16, No 4 (2023) | Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. N. Gromov, O. V. Tikhonova | ||
| "... . Methods of proteomic analysis of peptide preparations were used. The analysis of Laennec® HPH peptide ..." | ||
| Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
| "... organ diseases. Polypeptide-containing drug Laennec contributes to the elimination of excessive iron ..." | ||
| Vol 16, No 3 (2023) | The role of ferritin in liver disease assessment | Abstract similar documents |
| V. G. Radchenko, V. B. Grinevich, E. S. Ivanyuk, L. B. Lazebnik | ||
| "... of peptide components of human placenta hydrolysate (Laennec®) impact on pathophysiological processes ..." | ||
| Vol 16, No 3 (2023) | An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis | Abstract similar documents |
| M. Imawari, M. Nagase, I. Yu. Torshin, O. A. Gromova | ||
| "... Objective: to evaluate the efficacy and safety of human placenta hydrolysate (HPH) Laennec ..." | ||
| Vol 18, No 1 (2025) | Clinical and diagnostic significance of isolated detection of IgA antibodies to deamidated gliadin peptides in IgA nephropathy patients | Abstract similar documents |
| M. E. Mantsaeva, D. I. Korabelnikov, A. G. Borisov | ||
| "... antigens, such as gluten. Patients with IgAN often have IgA antibodies to deamidated gliadin peptides ..." | ||
| Vol 17, No 4 (2024) | Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... of alogliptin-pioglitazone combination versus glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Material ..." | ||
| Vol 18, No 1 (2025) | Systematic analysis of molecules regulating nitric oxide (NO) metabolism and vascular endothelium condition | Abstract similar documents |
| I. Yu. Torshin, A. G. Chuchalin, O. A. Gromova | ||
| Vol 17, No 2 (2024) | Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin | ||
| "... -adrenoceptors, adenosine receptors, glucagon-like peptide, sphingosine phosphate and peroxisome proliferators ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... state procurement of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in 2021, we ..." | ||
| Online First | Osteoarthritis therapy misconcepts | Abstract similar documents |
| O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov | ||
| "... on bioactive concentrate of small sea fish and glycoaminoglycan-peptide complex do not belong to SYSADOAs ..." | ||
| Vol 16, No 2 (2023) | From misconceptions to reasonable osteoarthritis patients therapy | Abstract similar documents |
| O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov | ||
| "... and glycoaminoglycan-peptide complex do not belong to SYSADOAs according to any of the existing generally recognized ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... substance-glycosaminoglycan-peptide complex (Romania), on the 1st day – 0.3 ml, on the 2nd day – 0.5 ml ..." | ||
| 1 - 14 of 14 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
